Prostatype Genomics AB PROGEN

OMXSTO · Sweden · Health Technology

SEK 0.0930-0.00 (-4.12%)

Market closed· Oct 1, 2026, 3:29 PM UTC· SEK · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Prostatype Genomics AB PROGEN

OMXSTO · Sweden · Health Technology

SEK 0.0930-0.00 (-4.12%)

Market closed· Oct 1, 2026, 3:29 PM UTC· SEK · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-89.80% · 6MFull-screen chart

Open SEK 0.0972High SEK 0.0986Low SEK 0.0902Close SEK 0.0932Volume 11.92M

Oct 1, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: SEK 0.0970
Day range: SEK 0.0900 – SEK 0.0990
52-week range: SEK 0.0900 – SEK 2.28
Volume: 11.92M
Market cap: SEK 67.06M
Avg. volume (1Y): 2.20M

Performance

1 week

-19.31%

1 month

-34.60%

3 months

-25.77%

6 months

-89.53%

Year to date

-75.79%

1 year

-82.68%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Medical Specialties
Country: Sweden
Exchange: OMXSTO
Shares outstanding: 691.32M
Employees: 7
ISIN: SE0023261532
Beta: 2.92

Technical view

Below averages

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceDec 09, 2025

Life Sciences Virtual Investor Forum Agenda Announced for December 11th

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, announced the agenda for the Life Sciences Virtual Investor Forum to be held December 11th. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE It is recommended that investors pre-register and run the online system check to exp

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.